By Fineline Cube 
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical results for its investigational drugs DZD8586 and DZD6008 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These findings highlight the potential of both drugs in treating various oncological conditions.
DZD8586 Clinical Results
DZD8586, a non-covalent blood-brain barrier (BBB) penetrant LYN/BTK dual inhibitor, demonstrated significant efficacy in blocking both BTK-dependent and independent BCR signaling pathways. This mechanism effectively inhibits the growth of multiple B-cell non-Hodgkin lymphoma (B-NHL) subtypes. In a study involving 51 patients with relapsed/refractory (r/r) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), DZD8586 achieved an objective response rate (ORR) of 84.2% at the 50 mg dose. Notably, the drug exhibited a tolerable safety profile with no dose-limiting toxicities reported.
DZD6008 Clinical Results
DZD6008, a highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to fully cross the BBB, showed robust preclinical activity against all tested EGFR mutations. In the first-in-human TIAN-SHAN2 Phase I/II study, early data indicated that 83.3% (10/12) of heavily pretreated EGFR-mutant non-small cell lung cancer (NSCLC) patients achieved target lesion tumor shrinkage. These results underscore the potential of DZD6008 in addressing treatment challenges in NSCLC.-Fineline Info & Tech